These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 12623559)
21. Effect of Interstitial Fluid Flow on Drug-Coated Balloon Delivery in a Patient-Specific Arterial Vessel with Heterogeneous Tissue Composition: A Simulation Study. Sarifuddin ; Mandal PK Cardiovasc Eng Technol; 2018 Jun; 9(2):251-267. PubMed ID: 29508375 [TBL] [Abstract][Full Text] [Related]
22. Restenosis after stenting of atherosclerotic renal artery stenosis: is there a rationale for the use of drug-eluting stents? Zeller T; Rastan A; Rothenpieler U; Müller C Catheter Cardiovasc Interv; 2006 Jul; 68(1):125-30. PubMed ID: 16755597 [TBL] [Abstract][Full Text] [Related]
23. Optimization of Drug Delivery by Drug-Eluting Stents. Bozsak F; Gonzalez-Rodriguez D; Sternberger Z; Belitz P; Bewley T; Chomaz JM; Barakat AI PLoS One; 2015; 10(6):e0130182. PubMed ID: 26083626 [TBL] [Abstract][Full Text] [Related]
24. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. Lemos PA; Farooq V; Takimura CK; Gutierrez PS; Virmani R; Kolodgie F; Christians U; Kharlamov A; Doshi M; Sojitra P; van Beusekom HM; Serruys PW EuroIntervention; 2013 May; 9(1):148-56. PubMed ID: 23685303 [TBL] [Abstract][Full Text] [Related]
25. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. Ali RM; Degenhardt R; Zambahari R; Tresukosol D; Ahmad WA; Kamar Hb; Kui-Hian S; Ong TK; bin Ismail O; bin Elis S; Udychalerm W; Ackermann H; Boxberger M; Unverdorben M EuroIntervention; 2011 May; 7 Suppl K():K83-92. PubMed ID: 22027736 [TBL] [Abstract][Full Text] [Related]
26. Dose model for stent-based delivery of a radioactive compound for the treatment of restenosis in coronary arteries. Janicki C; Hwang CW; Edelman ER Med Phys; 2003 Oct; 30(10):2622-8. PubMed ID: 14596298 [TBL] [Abstract][Full Text] [Related]
28. Effect of blood flow on near-the-wall mass transport of drugs and other bioactive agents: a simple formula to estimate boundary layer concentrations. Rugonyi S J Biomech Eng; 2008 Apr; 130(2):021010. PubMed ID: 18412497 [TBL] [Abstract][Full Text] [Related]
29. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Ng VG; Mena C; Pietras C; Lansky AJ Eur J Clin Invest; 2015 Mar; 45(3):333-45. PubMed ID: 25615282 [TBL] [Abstract][Full Text] [Related]
30. Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study. Adriaenssens T; Dens J; Ughi G; Coosemans M; Onsea K; Dubois C; Sinnaeve P; Vrolix M; Desmet W EuroIntervention; 2011 May; 7 Suppl K():K100-5. PubMed ID: 22027717 [TBL] [Abstract][Full Text] [Related]
31. Flow-Mediated Drug Transport from Drug-Eluting Stents is Negligible: Numerical and In-vitro Investigations. Vijayaratnam PRS; Reizes JA; Barber TJ Ann Biomed Eng; 2019 Mar; 47(3):878-890. PubMed ID: 30552528 [TBL] [Abstract][Full Text] [Related]
32. Modelling drug-eluting stents. McGinty S; McKee S; Wadsworth RM; McCormick C Math Med Biol; 2011 Mar; 28(1):1-29. PubMed ID: 20413417 [TBL] [Abstract][Full Text] [Related]
33. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661 [TBL] [Abstract][Full Text] [Related]
34. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis. El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402 [TBL] [Abstract][Full Text] [Related]
35. A general model of coupled drug release and tissue absorption for drug delivery devices. McGinty S; Pontrelli G J Control Release; 2015 Nov; 217():327-36. PubMed ID: 26390809 [TBL] [Abstract][Full Text] [Related]
36. Local drug delivery for treatment of coronary and peripheral artery disease. Gertz ZM; Wilensky RL Cardiovasc Ther; 2011 Dec; 29(6):e54-66. PubMed ID: 20553281 [TBL] [Abstract][Full Text] [Related]
37. In-stent restenosis: the gold standard has changed. Chin K EuroIntervention; 2011 May; 7 Suppl K():K43-6. PubMed ID: 22027726 [TBL] [Abstract][Full Text] [Related]
38. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828 [TBL] [Abstract][Full Text] [Related]
39. Mathematical modelling of NABD release from endoluminal gel paved stent. Davia L; Grassi G; Pontrelli G; Lapasin R; Perin D; Grassi M Comput Biol Chem; 2009 Feb; 33(1):33-40. PubMed ID: 18799356 [TBL] [Abstract][Full Text] [Related]
40. Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms. Siepmann J; Siepmann F; Florence AT Int J Pharm; 2006 May; 314(2):101-19. PubMed ID: 16647231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]